

Amendments to the Claims:

This listing of claims will replace all prior versions, and listing, of claims in the application:

Listing of Claims:

Claims 1-44 (Canceled).

45. (New) A method of treating SARS-coronavirus infection, comprising administering an effective amount of an interferon to a patient, wherein the interferon is IFN α -n1, IFN α -n3, human leukocyte IFN α or IFN β -1b.

46. (New) The method of claim 45 wherein the interferon is recombinant.

47. (New) The method of claim 46 wherein the interferon is recombinantly produced in *E. coli*.

48. (New) The method of claim 46 wherein the interferon is recombinantly produced in mammalian cells.

49. (New) The method of claim 46 further comprising administering an additional antiviral agent in combination with the interferon.

50. (New) The method of claim 49 wherein the additional antiviral agent is ribavirin.

51. (New) A method of inhibiting SARS-coronavirus infection, comprising administering an interferon to a cell capable of being infected with SARS-CoV, wherein the interferon is IFN α -n1, IFN α -n3, human leukocyte IFN α or IFN β -1b.

52. (New) The method of claim 51 wherein the interferon is recombinant.

53. (New) The method of claim 52 wherein the interferon is recombinantly produced in *E. coli*.

54. (New) The method of claim 52 wherein the interferon is recombinantly produced in mammalian cells.

55. (New) The method of claim 52 wherein the cell is in a patient.
56. (New) The method of claim 52 wherein the cell is a cell in vitro.
57. (New) The method of claim 56 wherein the cell is a VERO 6 cell, a peripheral blood leukocyte or a THP-1 monocyte.
58. (New) The method of claim 52 further comprising administering to the cell an additional antiviral agent in combination with the interferon.
59. (New) The method of claim 58 wherein the additional antiviral agent is ribavirin.
60. (New) A kit comprising an interferon and instructions for using the interferon to treat SARS-coronavirus infection, wherein the interferon is IFN α -n1, IFN α -n3, human leukocyte IFN α or IFN β -1b.
61. (New) A kit comprising an interferon and instructions for using the interferon to inhibit SARS-coronavirus infection, wherein the interferon is IFN α -n1, IFN α -n3, human leukocyte IFN α or IFN β -1b.
62. (New) The kit of claim 60 wherein the interferon is recombinant.
63. (New) The kit of claim 62 wherein the interferon is recombinantly produced in E. coli.
64. (New) The kit of claim 62 wherein the interferon is recombinantly produced in mammalian cells.
65. (New) The kit of claim 62 further comprising an additional antiviral agent.
66. (New) The kit of claim 65 wherein the additional antiviral agent is ribavirin.
67. (New) The kit of claim 61 wherein the interferon is recombinant.
68. (New) The kit of claim 67 wherein the interferon is recombinantly produced in E. coli.
69. (New) The kit of claim 67 wherein the interferon is recombinantly produced in mammalian cells.

70. (New) The kit of claim 67 further comprising an additional antiviral agent.
71. (New) The kit of claim 70 wherein the additional antiviral agent is ribavirin.